JP2017507943A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507943A5 JP2017507943A5 JP2016553897A JP2016553897A JP2017507943A5 JP 2017507943 A5 JP2017507943 A5 JP 2017507943A5 JP 2016553897 A JP2016553897 A JP 2016553897A JP 2016553897 A JP2016553897 A JP 2016553897A JP 2017507943 A5 JP2017507943 A5 JP 2017507943A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- neu
- osteosarcoma
- listeria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 30
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 26
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 26
- 241000186781 Listeria Species 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 201000008968 osteosarcoma Diseases 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 230000002503 metabolic effect Effects 0.000 claims description 11
- 108700026244 Open Reading Frames Proteins 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 241000282465 Canis Species 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 4
- 108010041525 Alanine racemase Proteins 0.000 claims description 3
- 150000008574 D-amino acids Chemical class 0.000 claims description 3
- 102000043129 MHC class I family Human genes 0.000 claims description 3
- 108091054437 MHC class I family Proteins 0.000 claims description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 102000004357 Transferases Human genes 0.000 claims description 3
- 108090000992 Transferases Proteins 0.000 claims description 3
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 230000002949 hemolytic effect Effects 0.000 claims description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 3
- 210000004898 n-terminal fragment Anatomy 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 201000008785 pediatric osteosarcoma Diseases 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 230000001018 virulence Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 206010006007 bone sarcoma Diseases 0.000 claims 1
- 101150012893 dat gene Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 14
- 230000004927 fusion Effects 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 5
- 208000006168 Ewing Sarcoma Diseases 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/189,008 | 2014-02-25 | ||
| US14/189,008 US20150366955A9 (en) | 2009-11-11 | 2014-02-25 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US14/268,436 | 2014-05-02 | ||
| US14/268,436 US20140234370A1 (en) | 2009-11-11 | 2014-05-02 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US201462076411P | 2014-11-06 | 2014-11-06 | |
| US62/076,411 | 2014-11-06 | ||
| PCT/US2015/017559 WO2015130810A2 (en) | 2014-02-25 | 2015-02-25 | Compositions and methods for the treatment of her2/neu over-expressing tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507943A JP2017507943A (ja) | 2017-03-23 |
| JP2017507943A5 true JP2017507943A5 (enExample) | 2018-08-02 |
Family
ID=54009773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553897A Pending JP2017507943A (ja) | 2014-02-25 | 2015-02-25 | Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3110942A4 (enExample) |
| JP (1) | JP2017507943A (enExample) |
| KR (2) | KR20160122829A (enExample) |
| CN (1) | CN106661538A (enExample) |
| AU (1) | AU2015223136A1 (enExample) |
| BR (1) | BR112016019534A2 (enExample) |
| CA (1) | CA2940646A1 (enExample) |
| IL (1) | IL247436A0 (enExample) |
| MX (1) | MX2016011114A (enExample) |
| RU (1) | RU2016137834A (enExample) |
| SG (1) | SG11201607036XA (enExample) |
| WO (1) | WO2015130810A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| WO2012125551A1 (en) | 2011-03-11 | 2012-09-20 | Advaxis | Listeria-based adjuvants |
| AU2013232291B8 (en) | 2012-03-12 | 2016-07-21 | Advaxis, Inc. | Suppressor cell function inhibition following listeria vaccine treatment |
| EP3107566A4 (en) | 2014-02-18 | 2017-10-11 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
| BR112016020364A2 (pt) * | 2014-03-05 | 2018-01-16 | Advaxis, Inc. | métodos para suscitar uma resposta de uma célula t antitumoral em um indivíduo tendo um tumor ou câncer e para aumentar a razão de células t efetoras sobre células t reguladoras no baço de um indivíduo |
| CA2946716A1 (en) | 2014-04-24 | 2015-10-29 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of producing the same |
| MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
| SG11201804957VA (en) | 2015-12-16 | 2018-07-30 | Gritstone Oncology Inc | Neoantigen identification, manufacture, and use |
| SG11201901979SA (en) | 2016-11-30 | 2019-04-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| US11179339B2 (en) | 2017-09-19 | 2021-11-23 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or listeria strains |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| KR20200090855A (ko) | 2017-11-22 | 2020-07-29 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원에 대한 접합 에피토프 제시 감소 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855320B2 (en) * | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
-
2015
- 2015-02-25 MX MX2016011114A patent/MX2016011114A/es unknown
- 2015-02-25 SG SG11201607036XA patent/SG11201607036XA/en unknown
- 2015-02-25 KR KR1020167025517A patent/KR20160122829A/ko not_active Ceased
- 2015-02-25 CN CN201580010568.4A patent/CN106661538A/zh active Pending
- 2015-02-25 KR KR1020247007406A patent/KR20240038103A/ko active Pending
- 2015-02-25 BR BR112016019534A patent/BR112016019534A2/pt not_active Application Discontinuation
- 2015-02-25 RU RU2016137834A patent/RU2016137834A/ru not_active Application Discontinuation
- 2015-02-25 CA CA2940646A patent/CA2940646A1/en active Pending
- 2015-02-25 JP JP2016553897A patent/JP2017507943A/ja active Pending
- 2015-02-25 EP EP15755609.3A patent/EP3110942A4/en not_active Withdrawn
- 2015-02-25 AU AU2015223136A patent/AU2015223136A1/en not_active Abandoned
- 2015-02-25 WO PCT/US2015/017559 patent/WO2015130810A2/en not_active Ceased
-
2016
- 2016-08-23 IL IL247436A patent/IL247436A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507943A5 (enExample) | ||
| JP2013526837A5 (enExample) | ||
| RU2016137834A (ru) | КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu | |
| US9969986B2 (en) | Virus like particle comprising modified envelope protein E3 | |
| KR102713707B1 (ko) | 신규 다가 나노입자 기반 백신 | |
| JP2017195888A5 (enExample) | ||
| ES2675825T3 (es) | Vacunación tumoral que involucra una respuesta inmunitaria contra la proteína propia CLDN18.2 | |
| JP2017513502A5 (enExample) | ||
| JP2018508212A5 (enExample) | ||
| JP2016156828A5 (enExample) | ||
| US20160200775A1 (en) | Virus like particle comprising modified envelope protein e3 | |
| JP2013532971A (ja) | ホモ二量体タンパク質コンストラクト | |
| CN118576699A (zh) | Hbv疫苗 | |
| KR20170092626A (ko) | 재조합 리스테리아 균주의 병용 요법 | |
| AU2017211387A1 (en) | Personalized delivery vector-based immunotherapy and uses thereof | |
| JP6406647B2 (ja) | 細胞性免疫誘導ワクチン | |
| Fioretti et al. | Recent advances in design of immunogenic and effective naked DNA vaccines against cancer | |
| JPWO2017175253A1 (ja) | エキソソーム標的ｄｎａワクチン | |
| KR20230004585A (ko) | 개별화된 치료용 항암 백신 | |
| Andreasson et al. | Murine pneumotropic virus chimeric Her2/neu virus‐like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors | |
| JPWO2020097393A5 (enExample) | ||
| EP2366709A1 (en) | Tumor vaccination involving a humoral immune response against self-proteins | |
| JP2020526202A5 (enExample) | ||
| KR20240024800A (ko) | 암호화된 아주반트를 포함하는 백신 조성물 | |
| US11844824B2 (en) | Nucleic acid molecules and methods of using the same |